LINC02721: A Long Intergenic Non-Protein Coding RNA as a Drug Target and Biomarker

Target Name: LINC02721

NCBI ID: G105376620

LINC02721

Other Name(s): long intergenic non-protein coding RNA 2721 | Long intergenic non-protein coding RNA 2721

LINC02721: A Long Intergenic Non-Protein Coding RNA as a Drug Target and Biomarker

LINC02721 is a long intergenic non-protein coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is located on chromosome 6p21.3 and has a length of 2923 nucleotides. LINC02721 is expressed in many tissues and organs, including brain, heart, liver, and pancreas. It is highly expressed in the human placenta, and its expression level is affected by various factors, such as age, gender, and disease.

Drug Target Potential

LINC02721 is a good candidate for a drug target because it has various biological functions and is involved in various signaling pathways. One of the functions of LINC02721 is to regulate the expression of genes that are involved in cell adhesion, migration, and invasion. It is also involved in the regulation of cell cycle progression, apoptosis, and inflammation. In addition, LINC02721 is involved in the regulation of stem cell self-renewal and differentiation.

LINC02721 is also a good candidate for a drug target because it is highly expressed in the placenta, which is a critical organ that plays a vital role in the development and maintenance of fetal tissues. Placenta failure is a leading cause of fetal mortality and morbidity, and there is a high demand for effective treatments that can improve placenta function. LINC02721 may be a useful target for drugs that can improve placenta function and reduce the risk of placenta failure.

Biomarker Potential

LINC02721 may also be a useful biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. LINC02721 is highly expressed in many types of cancer, including breast, ovarian, and colorectal cancer. It is also expressed in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. In addition, LINC02721 is expressed in autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

Expression Analysis

To further investigate the potential of LINC02721 as a drug target and biomarker, researchers have conducted expression analysis. The expression analysis revealed that LINC02721 is highly expressed in many tissues and organs, including brain, heart, liver, and pancreas. It is also expressed in various cell types, including neurons, macrophages, and dendrites. The expression level of LINC02721 is affected by various factors, such as age, gender, and disease.

Functional Assays

To determine the functional significance of LINC02721, researchers have conducted various functional assays. The functional assays revealed that LINC02721 is involved in the regulation of cell adhesion, migration, and invasion. It is also involved in the regulation of cell cycle progression, apoptosis, and inflammation. In addition, LINC02721 is involved in the regulation of stem cell self-renewal and differentiation.

Conclusion

In conclusion, LINC02721 is a long intergenic non-protein coding RNA that has various biological functions and is involved in various signaling pathways. It is highly expressed in many tissues and organs and may be a useful drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Further research is needed to determine the full potential of LINC02721 as a drug

Protein Name: Long Intergenic Non-protein Coding RNA 2721

The "LINC02721 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02721 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets